BioSpace News Archive

Blue Eye Soft is excited to announce that the U.S. Patent Office has officially awarded a utility patent for the company’s artificial intelligence (AI) technology which powers a clinical decision support tool that analyzes chest x-rays to more rapidly detect COVID-19, and other illness such as cancer, developing in lungs.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Richard Beckman, M.D., has joined Adverum as the company’s chief medical officer (CMO).

Biogen Inc. and Xbrane Biopharma AB announced that they have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane™, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA® 1.

Guardant Health, Inc., a leading precision oncology company, announced it will be participating virtually in the following investor conferences.

Hanger, Inc., a leading provider of orthotic and prosthetic patient care services and solutions, announced a preliminary estimate of certain results for the year ended December 31, 2021.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020.

Biovica, active in cancer diagnostics, announces that it has received full feedback from the FDA on its updated 510-application enabling a clear plan for the submission process.

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”) and Nano Precision Medical, Inc. (“NPM”), today announced that they have entered into a definitive agreement under which privately held NPM will merge with a wholly owned subsidiary of Second Sight in an all-stock transaction.

Vera Therapeutics, Inc., a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced that it has commenced a public offering, subject to market and other conditions, to issue and sell 4,000,000 shares of its Class A common stock.

Accuray Incorporated announced its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 15-17, 2022.